Asbis Enterprises PLC — M&A Activity 2023

Mar 28, 2023

Title: Investment in Theramir Ltd.

Legal basis: Art. 17 ust.1 MAR - inside information

Message: The Board of Directors of ASBISc Enterprises Plc ("ASBIS")hereby informs that ASBIS signed an agreement according to whichacquired 4.5% shares of the company Theramir Ltd with its registeredoffice in Limassol (Cyprus).

The price for the purchased shares was EUR 800,000

The acquisition was financed from the own Company's funds.

Theramir Ltd is a Cypriot biotech company, founded in 2016, that dealswith developing stem cell and RNA-based technologies for the diagnosisand treatment of cancer disease. Theramir's proprietary cancertherapeutics utilize microRNAs (miRNAs), a novel class of smallnon-coding RNAs that can regulate many genes and pathways involved incancer growth and metastasis.

The investment in Theramir Ltd is a continuity of the

ASBIS Group's strategy is to diversify its activities by investing incompanies from the biomedical sector that are at an early stage ofdevelopment and which operate in a very promising market.

In previous years ASBIS invested in biotechnology, companies includingEMBIO Diagnostics Ltd, RSL Revolutionary Labs Ltd. and Promed BioscienceLtd.